Kyntra Bio to Present at H.C. Wainwright 28th Annual Global Investment Conference

Kyntra Bio will present at the H.C. Wainwright Conference from September 14-16, 2026, in New York.

Quiver AI Summary

Kyntra Bio announced that its management, including CEO Thane Wettig, will participate in the H.C. Wainwright 28th Annual Global Investment Conference in New York from September 14-16, 2026. Wettig will present the company on September 15 at 4:00 PM ET, with a live webcast available for interested parties. The management team will also conduct one-on-one meetings with investors during the conference. Kyntra Bio focuses on developing novel therapies for oncology and rare diseases, with its drug Roxadustat approved in multiple countries for treating anemia in chronic kidney disease. Additionally, the company is advancing FG-3246 in Phase 2 trials for prostate cancer. More information can be found on their website.

Potential Positives

Kyntra Bio will present at a major investment conference, potentially increasing visibility and interest from investors.
The attendance and presentation by the CEO may enhance the company's credibility and attract further investment.
The live webcast of the presentation allows for wider reach and engagement with potential investors and stakeholders.
The company is advancing its biopharmaceutical pipeline, with ongoing research in significant areas like oncology and rare diseases, indicating a commitment to innovation.

Potential Negatives

Presence at a significant investment conference may suggest Kyntra Bio is actively seeking to communicate with investors about its current position, potentially indicating underlying concerns about investor confidence or recent performance.
The mention of ongoing evaluations for a Phase 3 trial could imply uncertainties or delays in the drug development process for roxadustat, which may be perceived negatively by investors looking for more definitive progress.
Competing with other biopharmaceutical companies at high-profile conferences might highlight potential vulnerabilities in Kyntra Bio's portfolio, particularly with regard to their development timeline for FG-3246 and other therapies.

FAQ

When is Kyntra Bio presenting at the H.C. Wainwright Conference?

Kyntra Bio will present on Tuesday, September 15, 2026, at 4:00 PM ET.

How can I watch Kyntra Bio's presentation?

A live webcast of the presentation will be available on Kyntra Bio's Investor webpage.

Where is the H.C. Wainwright Conference being held?

The conference is taking place in New York, NY, from September 14 to 16, 2026.

Who will be presenting for Kyntra Bio?

Thane Wettig, the Chief Executive Officer of Kyntra Bio, will deliver the company presentation.

How can investors schedule a meeting with Kyntra Bio management?

Interested investors should contact their representative at H.C. Wainwright for one-on-one meetings.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$KYNB Insider Trading Activity

$KYNB insiders have traded $KYNB stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $KYNB stock by insiders over the last 6 months:

THANE WETTIG (CEO) purchased 2,800 shares for an estimated $19,852

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$KYNB Hedge Fund Activity

We have seen 5 institutional investors add shares of $KYNB stock to their portfolio, and 21 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

MARSHALL WACE, LLP removed 32,502 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $220,363
DRW SECURITIES, LLC removed 30,420 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $206,247
UBS GROUP AG removed 19,734 shares (-71.5%) from their portfolio in Q2 2026, for an estimated $148,991
CITADEL ADVISORS LLC removed 16,756 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $113,605
GSA CAPITAL PARTNERS LLP added 15,697 shares (+inf%) to their portfolio in Q2 2026, for an estimated $118,512
NORTHERN TRUST CORP removed 12,852 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $87,136
JANE STREET GROUP, LLC removed 12,228 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $92,321

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$KYNB Price Targets

Multiple analysts have issued price targets for $KYNB recently. We have seen 2 analysts offer price targets for $KYNB in the last 6 months, with a median target of $32.5.

Here are some recent targets:

Jay Olson from Oppenheimer set a target price of $35.0 on 07/07/2026
Michael G. King Jr. from Rodman & Renshaw set a target price of $30.0 on 06/09/2026

Full Release

SAN FRANCISCO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today announced that the company’s management will be attending and presenting at the H.C. Wainwright 28 ^th Annual Global Investment Conference being held September 14-16, 2026, in New York, NY.

Thane Wettig, Chief Executive Officer of Kyntra Bio, will deliver a company presentation on Tuesday, September 15 at 4:00 PM ET. A live webcast of the presentation will be available here .

Kyntra Bio’s management team will be available for one-on-one meetings during the conference. Interested investors should contact their representative at H.C. Wainwright. The live audio webcast of the event will also be available to investors and other interested parties on the “ Events & Presentations ” section of the Kyntra Bio Investor webpage at www.kyntrabio.com . The replay will be available for 90 days following the event.

About Kyntra Bio
Kyntra Bio is a biopharmaceutical company focused on development of novel therapies in oncology and rare disease. Roxadustat (爱瑞卓 ^® , EVRENZO™) is currently approved in Europe, Japan, China, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis. The Company continues to evaluate the development plan for the Phase 3 trial of roxadustat in anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) in the U.S. FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46, is in Phase 2 development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of FG-3180, an associated CD46-targeted PET biomarker. For more information, please visit www.kyntrabio.com .

For Investor Inquiries:
David DeLucia, CFA
Senior Vice President and Chief Financial Officer
[email protected]